Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
16 studies found for:    Pegasus
Show Display Options
Rank Status Study
1 Unknown  Evaluating PEGASUS - a Group Intervention for Young People With an Autism Spectrum Disorder
Condition: Efficacy of PEGASUS
Intervention: Behavioral: PEGASUS
2 Completed
Has Results
PEGASUS CRT Study: Atrial Support Study in Cardiac Resynchronization Therapy
Condition: Heart Failure
Intervention: Device: Atrial support pacing through cardiac resynchronization therapy. Device: RENEWAL family of CRT-D devices
3 Active, not recruiting Study of the Efficacy of New Non-invasive Prenatal Tests for Screening for Fetal Trisomies Using Maternal Blood
Conditions: Trisomy 21;   Trisomy 18;   Trisomy 13
Interventions: Other: Integrated prenatal screening for Down's syndrome;   Other: Serum QUAD Assay for aneuploidy screening;   Other: Semiconductor MPSS NIPT assay using ccfDNA in maternal blood;   Other: Optical-based MPSS NIPT assay using ccfDNA in maternal blood;   Other: Harmony™ Test (Ariosa Diagnostics)
4 Recruiting To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada.
Condition: Wet Macular Degeneration
Intervention: Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
5 Not yet recruiting Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Degarelix in combination with radiation therapy;   Drug: approved GnRH agonist in combination with radiation therapy
6 Active, not recruiting Randomized Study of Integration Success of Osseotite Dental Implants Placed Using Different Insertion Procedures
Conditions: Partial Edentulism;   Tooth Disease
Interventions: Procedure: High torque insertion;   Procedure: Low torque insertion
7 Completed
Has Results
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Conditions: Myocardial Infarction;   Cardiovascular Death;   Atherothrombosis;   Stroke
Interventions: Drug: Ticagrelor 90 mg;   Drug: Ticagrelor 60 mg;   Drug: Ticagrelor Placebo
8 Completed Footwear Minimalism Study
Condition: Healthy Runners
Interventions: Other: Nike Pegasus;   Other: Nike Free 3.0;   Other: Vibram Five Fingers Shoe
9 Completed Interferon Treatment for Patients With Chronic Hepatitis C and End Stage Renal Disease
Conditions: Chronic Hepatitis C;   End Stage Renal Disease
Interventions: Drug: Peginterferon alfa-2a;   Drug: Interferon alfa-2a
10 Not yet recruiting A Randomized, Pharmacodynamic Comparison of Low Dose Ticagrelor to Clopidogrel in Patients With Prior Myocardial Infarction
Conditions: Myocardial Infarction;   Diabetes Mellitus;   Renal Disease;   Coronary Artery Disease
Interventions: Drug: Ticagrelor;   Drug: Clopidogrel
11 Completed HsTnT in Stable Coronary Artery Disease
Condition: Coronary Artery Disease
Intervention: Other: Progress of CHD
12 Recruiting Preventive Effects of Ginseng Against Atherosclerosis
Condition: Ischemic Stroke
Interventions: Dietary Supplement: Ginseng;   Dietary Supplement: Placebo
13 Terminated
Has Results
Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma
Conditions: Anaplastic Astrocytoma;   Glioblastoma
Interventions: Drug: trabedersen;   Drug: temozolomide;   Device: Drug delivery system for administration of AP 12009;   Procedure: Placement of Drug Delivery System;   Drug: carmustine;   Drug: lomustine
14 Completed Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus
Conditions: Uremic Pruritus;   Pruritus
Interventions: Drug: nalbuphine HCl ER tablets 60 mg BID;   Drug: nalbuphine HCl ER tablets 120mg BID;   Drug: Placebo tablets BID
15 Completed Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Conditions: Anemia;   Chronic Kidney Disease (CKD)
Interventions: Drug: HX575 epoetin alfa;   Drug: US-licensed epoetin alfa
16 Completed Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus
Conditions: Uremic Pruritus;   Pruritus
Interventions: Drug: nalbuphine HCl ER 60mg BID;   Drug: nalbuphine HCl ER 90mg BID;   Drug: nalbuphine HCl ER 120mg BID

Indicates status has not been verified in more than two years